DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors Clinical Trial

Official title:

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05785754
• Other study ID #: DCSZ11-101
• Status: Recruiting
• Phase: Phase 1
• Start date: June 28, 2023
• Est. completion date: May 2025

Study information

• Verified date: March 2024
• Source: DynamiCure Biotechnology
• Contact: Sr Medical Director
• Phone: +1 (781) 373-9136
• Email: alejandrogomez[@]dynamicure.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11, an anti-CD93 monoclonal antibody, as a monotherapy and in combination in patients with advanced or metastatic solid tumors.

Description:

The drug being tested in this study is called DCSZ11. DCSZ11 is being tested to treat people who have advanced or metastatic solid tumors. The study will include a dose escalation phase and a dose expansion phase. The study will enroll approximately 138 patients in dose escalation, and approximately 113 participants in the dose expansion phase. Participants will receive escalating doses of DCSZ11 and a fixed dose of pembrolizumab until DCSZ11 doses for phase 1b are selected: - Phase 1a DCSZ11 monotherapy Dose Escalation. - Phase 1a DCSZ11 in combination with fixed dose of pembrolizumab Dose Escalation. Once Phase 1b doses are selected for Phase 1b, participants of select advanced or metastatic solid tumors will receive DCSZ11 in below defined cohorts in Phase 1b: - Phase 1b cohort 1 NSCLC. - Phase 1b cohort 2 Microsatellite Stable Colorectal Cancer (MSS-CRC) without liver involvement. - Phase 1b cohort 3 MSS-CRC with liver involvement. This multi-center trial will be conducted worldwide. The overall time to participate in this study is 60 months. Participants will make multiple visits to the clinic, and survival follow-up for a maximum of up to 12 months after the last dose of the study drug.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 257
• Est. completion date: May 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Selected Inclusion Criteria:

1. Male or female patients = 18 years of age.

2. Have a histologically or cytologically documented, advanced (metastatic and/or unresectable) solid tumor that has progressed on or after standard therapy (relapsed/refractory patients; patients must have failed at least one prior line of therapy) or for whom there is no effective standard therapy based on the Investigator's judgment.

3. At least 1 measurable lesion according to RECIST Version 1.1.

4. Patients must have a lesion that can be biopsied with acceptable clinical risk and agree to have a biopsy at Screening and on treatment.

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

6. Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed within 14 days prior to the first dose of study drug.

7. For female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy test and agree to use highly effective contraception.

8. For men who are not surgically sterile must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating sperm.

9. The patient is capable of understanding and complying with the protocol and has signed the required ICF. The appropriate ICF must be signed before relevant study procedures are performed. If applicable, the female partner of a male patient understands and signs the pregnant partner's ICF.

Selected Exclusion Criteria:

1. Received systemic anticancer treatments or investigational products within 14 days before the first dose of the study drug or 5 half-lives, whichever is shorter.

2. Received extended field radiotherapy =4 weeks before the start of treatment (=7 days for limited field radiation for palliation outside the chest or brain).

3. Patients with second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the patient is not on active anticancer therapy.

4. Systemic arterial thrombotic or embolic events, such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 3 months prior to the first dose of study drug.

5. Systemic venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 1 month prior to the first dose of study drug. Patients with venous thrombotic events prior to the first dose of study drug on stable anticoagulation therapy are eligible.

6. Left ventricular ejection fraction (LVEF) < 50%

7. Major surgery within 4 weeks and minor surgery within 2 weeks of the first dose of study drug; following surgeries, all surgical wounds must be healed and free of infection or dehiscence.

8. Marked proteinuria = 2 g/24 hours and/or nephrotic syndrome. Patients with proteinuria 2+ or greater urine dipstick reading should undergo further assessment, eg, a 24-hour urine collection.

9. For patients receiving a combination with pembrolizumab:

1. History of adverse events related to immunotherapy that required treatment discontinuation.

2. History of autoimmune disease requiring systemic immunosuppressive therapy with daily doses of prednisone >10 mg/day or equivalent doses, or any other form of immunosuppressive therapy. Hormone therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered an excluded form of systemic treatment of an autoimmune disease.

3. History of noninfectious pneumonitis that required steroids or a history of interstitial lung disease.

4. Evidence of active, noninfectious pneumonitis.

5. History of allogeneic tissue or solid organ transplant.

10. History of any of the following =6 months before first dose: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias >Grade 2, or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.

11. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or has compromised ability to provide written informed consent.

12. Female patients who are pregnant or lactating and breastfeeding.

Related Conditions & MeSH terms

• Advanced or Metastatic Solid Tumors
• Neoplasms

Intervention

Drug:
• DCSZ11
A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
• Pembrolizumab
Pembrolizumab injection

Locations

Country	Name	City	State
Australia	Southern Oncology Clinical Research Unit (SOCRU)	Bedford Park	South Australia
Australia	Monash Health	Clayton	Victoria
Australia	Cabrini Hospital	Malvern	Victoria
Australia	Linear Clinical Research Limited	Nedlands	Western Australia
Australia	Scientia Clinical Research	Randwick	New South Wales
Australia	St Vicent's Hospital	Sydney	New South Wales
Australia	The Queen Elizabeth Hospital (TQEH)	Woodville South	South Australia
United States	University of Colorado	Aurora	Colorado
United States	University of Alabama	Birmingham	Alabama
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	MonteFiore	Bronx	New York
United States	Mayo Clinic	Jacksonville	Florida
United States	University of Miami	Miami	Florida
United States	Yale Cancer Center	New Haven	Connecticut
United States	Mayo Clinic	Phoenix	Arizona
United States	Mayo Clinic	Rochester	Minnesota
United States	HonorHealth	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
DynamiCure Biotechnology

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1a: Incidence of dose limiting toxicites (DLTs)		21 days
Primary	Phase 1a: Frequency and severity of treatment emergent adverse events		up to 3 years
Primary	Phase 1b: Overall response rate (ORR) per Investigator-assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST)		1 year
Secondary	Phase 1a: Overall response rate (ORR) per Investigator-assessed RECIST v1.1		1 year
Secondary	Phase 1a and b: Overall response rate (ORR) per Investigator-assessed consensus guideline developed by the RECIST Working Group for the use of modified RECIST, Version 1.1 in cancer immunotherapy trials (iRECIST)		1 year
Secondary	Phase 1a and b: Duration of response (DOR) as determined per Investigator assessment by RECIST v1.1 and iRECIST		1 year
Secondary	Phase 1 a and b: Disease control rate (DCR) as determined per Investigator assessment by RECIST v1.1 and iRECIST.		1 year
Secondary	Phase 1a and b: Progression free survival (PFS) as determined per Investigator assessment by RECIST v1.1 and iRECIST.		3 years
Secondary	Phase 1 a and b: Overall survival (OS)		3 years
Secondary	Phase 1 and b: Pharmacokinetic parameters of DCSZ11		2 years
Secondary	Phase 1 a and b: Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs) against DCSZ11		2 years